MAPT and Alzheimer disease: Furthermore, our work encourages the refinement of biomarker-based classification of AD (“ATN” scheme) [26], as some individuals may be classified as “Aβ positive, plasma or CSF p-tau181 positive, and tau-PET negative.” Synthesizing the findings in this study, together with previous literatures [33, 36], a model of biomarker trajectories in AD may therefore be updated (Fig. 5).